Skip to main content
Asmita Mishra, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

AsmitaMishraMD

Oncology • Tampa, FL

Physician

Request Appointment

Overview of Dr. Mishra

Dr. Asmita Mishra is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from St. George's University School of Medicine and has been in practice 10 years. She is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 50 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2010 - 2013
  • University of Louisville School of Medicine
    University of Louisville School of MedicineResidency, Internal Medicine, 2007 - 2010
  • St. George's University School of Medicine
    St. George's University School of MedicineClass of 2007

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2013 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
    Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
    Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
    Asmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
    Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021
  • Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
    Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021
  • Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
    Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AMLJuly 21st, 2021
  • Join now to see all

Hospital Affiliations

Dr. Asmita Mishra, Dr. Asmita Mishra, MD, Dr. A Mishra